Cohort information

ITALY				WP2
Organization		University of Verona
Name of cohort		UNIVR
Referring partner		UNIVR
Cohort Information	Country(-ies), cities, regions or centers involved	Verona, Italy
	Time of data collection	04/2021	Ongoing
	Enrolment	Inactive
	Study setting	Single center
Population	Age	Adolescents,Adults,Elderly
	Type	Prospective
	Total number of patients	2242
	Site of enrolment (WP2)	Outpatient,Inpatient,ICU
Data collection	Clinical data	True
	Serological data	True
	Genetic data	True
	Sample collection	True
	Sample collected	Whole blood	Yes
		PBMC	Yes
		Dry-spot blood	No
		Plasma	Yes
		Serum	Yes
		Stool	Yes
		NP swabs	Yes
		Other	None
Description	UNIVR enrolled hospitalized and non-hospitalized patients with confirmed diagnosis of SARS-CoV-2 infection. Data can be shared once ORCHESTRA WP2 protocol has been submitted and approved by the Ethic Committee and a dedicated informed consent will be signed from patients who will be revaluated for follow-up.
Publications	- Determinants of Persistence of Symptoms and Impact on Physical and Mental Wellbeing in Long COVID: A Prospective Cohort Study [Journal of Infection] - Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study [Eur J Clin Microbiol Infect Dis] - Clinical Impact of Monoclonal Antibodies in the Treatment of High-Risk Patients with SARS-CoV-2 Breakthrough Infections: The ORCHESTRA Prospective Cohort Study [Biomedicines] - Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron Variant of Concern [eLife] - Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments [Journal of Clinical Investigation] - Clinical phenotypes and quality of life to define post-COVID-19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort [eClinicalMedicine]